1. Market Research
  2. > Pharmaceutical Market Trends
PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

  • August 2017
  • 262 pages
  • ID: 5206659
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

Summary
Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

It is estimated that pharmaceutical sales in the migraine market were approximately US$3.3 Billion throughout the 7MM in 2016. The US contributed to over 70% of these sales, generating about US$2.3 billon, driven mainly by the sale of triptans (around US$1.5 Billion) and Botox (almost US$0.5 Billion). The only triptan to remain patented in the US in 2016 was Pfizer’s Relpax, which consequently is the highest-selling brand within this class.

Global migraine sales are expected to grow to around US$8.5 Billion by 2026, at a Compound Annual Growth Rate (CAGR) of over 10%. The growth will be driven by the launch of several late-stage pipeline products, particularly the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) erenumab, galcanezumab, fremanezumab, and eptinezumab, developed by Amgen, Eli Lilly, Teva, and Alder respectively.

The major drivers of growth in the migraine market during the forecast period include -
- The launch and uptake of Eli Lilly’s lasmiditan and Allergan’s ubrogepant, which have novel mechanisms that satisfy unmet needs in the acute treatment market.
- The launch and uptake of Amgen’s erenumab, Eli Lilly’s galcanezumab, Teva’s fremanezumab, Alder’s eptinezumab, and Allergan’s atogepant, which are the first migraine-specific prophylactic treatments.
- The high annual cost of therapy for mAbs, which will mean they will generate high sales.
- A rising prevalence of migraine in the 7MM throughout the forecast period, which will lead to an increase in the diagnosed and treated population and will drive sales.

The report "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026", provides Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Pfizer, Amgen, Eli Lilly, Teva, Alder Biopharmaceuticals, Merck & Co, Allergan, Zogenix, RedHill BioPharma, Desitin, Grupe JUSTE, Grunenthal.

Scope
- Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline ...

Fibromyalgia - Pipeline Review, H2 2019

Fibromyalgia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Fibromyalgia - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H2 2019, provides an overview of the Fibromyalgia (Central Nervous System) ...

Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2019

Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2019SummaryMitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on